The longevity market is the next place these drugs are going, and it moves faster than evidence does — faster than the trial evidence that exists can support. This review is a careful version of the argument, which makes it a good place to see exactly where the argument currently stops.
The case, as its authors put it
These drugs reduce major cardiovascular events, all-cause mortality and systemic inflammation in randomized trials. [1] The review cites SELECT’s 19% reduction in all-cause mortality, hazard ratio 0.81, in people with obesity and without diabetes, and FLOW’s 24% reduction in its primary kidney composite, hazard ratio 0.76.
It then makes an inferential move worth marking: it describes those effect sizes as exceeding what glycemic and weight-related improvements alone would predict. That is a comparison against a model of how much benefit weight loss ought to produce, not a measurement of anything. It may well be right. It is an argument rather than a result.
The clocks
The newest piece is the interesting one. The review reports that randomized evidence published in 2025 showed significant deceleration of three validated DNA methylation clocks — DunedinPACE, PCGrimAge and PhenoAge — over 32 weeks of semaglutide therapy. That finding is described here as the review describes it; this desk has not read the underlying trial.
What the review itself says is missing
Its own list is long and specific: definitive trials with prespecified epigenetic aging endpoints, durability follow-up, body-composition assessment, prespecified sex-stratified analyses, and adequate representation of diverse populations. None of those exist yet.
It flags the pending EVOKE and EVOKE+ readouts in early Alzheimer’s disease as particularly consequential, which is fair — a hard clinical endpoint in a neurodegenerative disease would say far more than any clock. That question has its own page here, and it is still open.
Why this matters commercially before it matters clinically
Because “slows biological aging” is a claim that can be made about a biomarker long before it can be made about a person, and there is an entire consumer longevity industry built on exactly that gap. Methylation clock tests are already sold direct to consumers. The pairing of those two products is predictable.
No seller on this roster offers a longevity indication and none claims one. If that changes, the question to ask is the one this review answers honestly about itself: which endpoint moved, and was it a thing that happened to people or a number that predicts things that happen to people? It is the same question every endpoint choice raises, and the answer is rarely in the headline.
The mechanisms the review names — hypothalamic receptor signaling, AMPK and SIRT1 pathways, short-chain fatty acids from the microbiome — are plausible and preclinical. Mechanistic plausibility is how every failed intervention in this field started, and it is worth about as much as a study with nobody to compare against. What sellers will eventually say about any of this is worth watching; what they say now is the baseline.